Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05049655

Multi-Center Clinical Database of Infants for the Investigation of Early Nutrition Biomarkers

An observational study to generate a long-term outcome database from medical records for infants who completed protocol SS-101-18 or infants who are breastfed, fed commercial formula, or fed a marketed ByHeart formula.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Age range

0 day–5 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Alabama Clinical Therapeutics, LLC (Cohort 1), Birmingham, Alabama, United States

Loading trial locations.

About this study

The first Cohort (Cohort 1) goals of the registry include: to compile a clinical database of children who were fed in SS-101-18 by breastfeeding, commercial formula, or ByHeart formula; to investigate any difference in demographics, growth, development, medical diagnoses, and outcomes between the feeding groups, and in particular to compare ByHeart formula-fed infants against commercial formula-fed infants, and referenced against breastfed infants.

The second Cohort (Cohort 2) goals of the registry include: to compile a clinical database of children who were fed by breastfeeding or commercial formula (including ByHeart formula); to describe any difference in growth, development, medical diagnoses, and outcomes based on early nutritional intake; and to inform or facilitate development of future ByHeart products.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cohort 1:

  • Active participation in SS-101-18 through Visit 9
  • Provision of signed and dated informed consent form (ICF) by parent or legally authorized representative (LAR)
  • Stated willingness to comply with all study procedures by parent or LAR.

Exclusion criteria

Cohort 1:

  • Did not participate in SS-101-18
  • Participated in SS-101-18 that withdrew from the study for any reason prior to Visit 9
  • Anything that in the opinion of the Investigator is likely to interfere with participation in the registry.

Inclusion criteria

Cohort 2:

  • Be less than 120 days old at the time of enrollment
  • Provision of signed and dated informed consent form (ICF) by parent or legally authorized representative (LAR)
  • Stated willingness to comply with all study procedures by parent or LAR.

Exclusion criteria

Cohort 2:

  • Participation in SS-101-18
  • Anything that, in the opinion of the Investigator, is likely to interfere with participation in the registry.
  • In the opinion of the investigator, has a diagnosed medical condition or genetic abnormality known to impact growth or development.

Treatment and study plan

Primary outcomes

  1. Cohort 1: Growth, Development, Diagnoses, and Long-term Outcomes

    Time frame: 5 years

    The registry will be utilized to investigate growth, development, diagnoses, and long-term outcomes of infants who received ByHeart study formula, commercially available formula, or breastmilk in the SS-101-18 protocol.

  2. Cohort 2: Growth, Development, Diagnoses, and Long-term Outcomes

    Time frame: 5 years

    A clinical database of children of all feeding options; to describe any difference in growth, development, medical diagnoses, and outcomes based on early nutritional intake

Sponsors and collaborators

Lead sponsor

ByHeart

Industry

Registry information

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Sep 20, 2021
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.